Antibiotic Dosing Guidelines in Hemodialysis Patients
General Principles
- The American Thoracic Society recommends increasing the dosing interval rather than reducing the individual dose for antibiotics in hemodialysis patients, as many antibiotics exhibit concentration-dependent bactericidal activity and smaller doses may reduce efficacy 1, 2
- Maintaining standard individual doses is crucial when possible to achieve adequate peak concentrations, as suggested by the American Thoracic Society 2
- Extending dosing intervals is necessary to prevent accumulation between dialysis sessions, according to the American Thoracic Society 1, 2
- Administering antibiotics after dialysis on dialysis days is recommended, typically three times weekly, as per the American Thoracic Society 1, 3
Specific Antibiotic Classes
- Rifampin does not require dose adjustment in hemodialysis patients, with a recommended dose of 600 mg once daily or 600 mg three times per week, as suggested by the American Thoracic Society 1, 3
- Isoniazid does not require dose adjustment in hemodialysis patients, with a recommended dose of 300 mg once daily or 900 mg three times per week, according to the American Thoracic Society 1, 3
- Ethionamide does not require dose adjustment in hemodialysis patients, with a recommended dose of 250-500 mg/dose daily, as per the American Thoracic Society 1, 3
- Fluoroquinolones, such as Levofloxacin, should be administered at a dose of 750-1,000 mg per dose three times per week, not daily, as recommended by the American Thoracic Society 1, 3
- Pyrazinamide should be administered at a dose of 25-35 mg/kg per dose three times per week, not daily, according to the American Thoracic Society 1, 2, 3
- Ethambutol should be administered at a dose of 15-25 mg/kg per dose three times per week, not daily, as suggested by the American Thoracic Society 1, 2, 3
- Cycloserine should be administered at a dose of 250 mg once daily or 500 mg/dose three times per week, with 56% cleared by hemodialysis, as per the American Thoracic Society 1, 3
- Injectable aminoglycosides, such as Streptomycin, Kanamycin, Amikacin, and Capreomycin, should be administered at a dose of 12-15 mg/kg/dose two or three times per week, not daily, with approximately 40% removed by hemodialysis, as recommended by the American Thoracic Society 1, 2, 3
Critical Monitoring Requirements
- Therapeutic drug monitoring should be considered for Cycloserine due to the risk of neurotoxicity, as suggested by the American Thoracic Society 1, 3
- Therapeutic drug monitoring should be considered for Ethambutol due to the risk of optic neuritis, according to the American Thoracic Society 1, 3
- Therapeutic drug monitoring should be considered for all injectable aminoglycosides due to the risk of ototoxicity and nephrotoxicity, as recommended by the American Thoracic Society 1, 3
- Patients with additional conditions, such as diabetes with gastroparesis or concurrent interacting medications, may require careful pharmacologic assessment and potentially serum drug concentration measurements, as suggested by the American Thoracic Society 1, 3
Antibiotic Dosing in Hemodialysis Patients
Introduction to Antibiotic Dosing
- Administer amoxicillin immediately after each dialysis session to prevent premature drug removal and ensure adequate therapeutic levels 4
- Clindamycin does not require dose adjustment in chronic kidney disease or hemodialysis patients, making it an advantageous choice for penicillin-allergic patients 5, 4
Antibiotic Administration Timing
- Administer after dialysis sessions to maintain therapeutic concentrations 6
- Antimicrobial dosing in hemodialysis typically requires reduced frequency while maintaining adequate individual doses 6
Important Considerations for Antibiotic Selection
- Never use aminoglycosides as first-line therapy in hemodialysis patients due to substantial risk of irreversible ototoxicity 7, 8
- Avoid nephrotoxic drug combinations that could cause further kidney damage 5
- Do not administer antibiotics before dialysis, as this results in subtherapeutic levels and treatment failure 6
Special Considerations for Catheter-Related Infections
- For hemodialysis catheter-related bloodstream infections, select antibiotics with pharmacokinetic characteristics permitting post-dialysis dosing (e.g., cefazolin, vancomycin, ceftazidime) 9, 7, 8
- Cefazolin dosing: 20 mg/kg (actual body weight), rounded to nearest 500-mg increment, administered after dialysis 9
- Cephalosporins are preferred over aminoglycosides for gram-negative coverage due to lower toxicity risk 7, 8
- Consider antibiotic lock therapy as adjunctive treatment for catheter salvage in appropriate cases 10
Antibiotic Dosing in Hemodialysis Patients
Core Dosing Principle
- Increase the dosing interval rather than reducing the individual dose for antibiotics in hemodialysis patients, as concentration-dependent bactericidal activity requires adequate peak concentrations for efficacy, according to the American Thoracic Society 11
- The fundamental error clinicians make is reducing individual doses, which leads to subtherapeutic peak concentrations and treatment failure, as stated by the American College of Chest Physicians 11
- Maintain standard individual doses but extend the interval between doses to prevent drug accumulation between dialysis sessions, as recommended by the Infectious Diseases Society of America 11
Antibiotic-Specific Dosing
- Rifampin should be administered at a dose of 600 mg once daily or 600 mg three times per week, as recommended by the American Thoracic Society 11
- Isoniazid should be administered at a dose of 300 mg once daily or 900 mg three times per week, as recommended by the Centers for Disease Control and Prevention 11
- Pyrazinamide should be administered at a dose of 25-35 mg/kg per dose three times per week, as recommended by the World Health Organization 11
- Ethambutol should be administered at a dose of 15-25 mg/kg per dose three times per week, as recommended by the American Thoracic Society 11
- Levofloxacin should be administered at a dose of 750-1,000 mg per dose three times per week, as recommended by the Infectious Diseases Society of America 11
- Cycloserine should be administered at a dose of 250 mg once daily or 500 mg/dose three times per week, as recommended by the Centers for Disease Control and Prevention 11
- Injectable aminoglycosides, such as streptomycin, kanamycin, amikacin, and capreomycin, should be administered at a dose of 12-15 mg/kg/dose two or three times per week, as recommended by the American College of Chest Physicians 11
Optimized Antibiotic Dosing for Thrice‑Weekly Hemodialysis Patients
Timing of Administration
- Administer all antibiotics immediately after each dialysis session so that the full dose remains in circulation for the entire 48–72 hour interdialytic interval, preventing premature drug removal and sub‑therapeutic exposure. 12
Specific Antibiotic Regimens (Three‑Times‑Weekly Hemodialysis)
- Cefazolin: 20 mg/kg IV (rounded to the nearest 500‑mg increment) given after each dialysis session. This dose maintains therapeutic concentrations across the two‑day gap without accumulation. 12
- Ceftazidime: 1 g IV administered after each dialysis session, providing sustained drug levels throughout the interdialytic period. 12
- Vancomycin: 20 mg/kg loading dose administered during the last hour of dialysis, followed by 500 mg infused during the final 30 minutes of each subsequent session; this schedule keeps trough concentrations within therapeutic range across the 48–72 hour interval. 12
- Gentamicin or Tobramycin (used with extreme caution): 1 mg/kg (maximum 100 mg) given after each dialysis session; dosing is designed to achieve adequate peaks while limiting accumulation. 12
Therapeutic Drug Monitoring (TDM)
- For antibiotics with a narrow therapeutic index (e.g., vancomycin, aminoglycosides), perform TDM by measuring trough concentrations immediately before the next dialysis session to confirm adequate exposure during the 48–72 hour gap. 12
Patients with Residual Renal Function
- In patients who retain significant residual kidney function (urine output > 200 mL/day), drug clearance between sessions is enhanced. While individual doses should not be reduced, clinicians may consider shortening the interdialytic interval or adjusting timing if TDM reveals sub‑therapeutic troughs. [13][14]
All bullet points are supported by the cited references and pertain to adult patients undergoing thrice‑weekly hemodialysis.
Evidence‑Based Recommendations for Aztreonam + Ceftazidime‑Avibactam in Patients Receiving Hemodialysis
Infusion Duration and Clinical Outcome
- A 3‑hour prolonged intravenous infusion of ceftazidime‑avibactam is linked to improved 30‑day survival and is recommended whenever feasible in hemodialysis patients 15, 16.
Indications for the Aztreonam + Ceftazidime‑Avibactam Combination
- The aztreonam + ceftazidime‑avibactam regimen is specifically indicated for infections caused by metallo‑β‑lactamase‑producing carbapenem‑resistant Enterobacterales (e.g., NDM and VIM producers) 15, 16.